Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACIT-1 in adult cancer patients
NCT03096093Phase 2Active, not recruiting
- Sponsor
- CancerVax
- Start
- Apr 2017
- Primary completion
- Dec 2026
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ACIT-1 in cancer (2 arms), sponsored by CancerVax. Primary endpoint: Toxicity at 20 weeks. Started Apr 2017; status: active, not recruiting.
02
Drugs
ACIT-1
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03096093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03096093.